实用医学杂志 ›› 2022, Vol. 38 ›› Issue (7): 786-790.doi: 10.3969/j.issn.1006⁃5725.2022.07.002

• 新型冠状病毒肺炎专栏 • 上一篇    下一篇

新型冠状病毒肺炎的药物治疗研究进展

江晶晶1,2 冯富娟1,2 高春1,2 于晓辉2 张久聪2   

  1.  1 甘肃中医药大学(兰州730000);2 中国人民解放军联勤保障部队第九四〇医院消化内科(兰州730050)

  • 出版日期:2022-04-10 发布日期:2022-04-10
  • 通讯作者: 张久聪 E⁃mail:zhangjiucong@163.com
  • 基金资助:
    第九四〇医院院内新冠基金项目(编号:20yjky020);火神山医院科研基金面上项目(编号:HSS⁃217)

Research progress in drug therapy for COVID⁃19

JIANG Jingjing*,FENG Fujuan,GAO Chun,YU Xiaohui, ZHANG Jiucong.   

  1. Gansu University of Traditional Chinese Medicine,Lanzhou 730000,China;*Department of Gas⁃ troenterology,the 940 Hospital of Joint Logistic Support Force of PLA,Lanzhou 730050,China 

  • Online:2022-04-10 Published:2022-04-10
  • Contact: ZHANG Jiucong E⁃mail:zhangjiucong@163.com

摘要:

2019 12 月底,一种由严重急性呼吸综合征冠状病毒 2(SARS⁃CoV⁃2)引起的新型冠状病毒 肺炎(corona⁃virus disease⁃2019,COVID⁃19)在全球迅速传播。通过积极防控和及时救治,我国境内疫情目 前已得到基本控制,仅在个别地区出现局部暴发和少数境外输入病例。但此次疫情在部分国家和地区仍 有蔓延,且目前尚无明确针对 COVID⁃19 的特效药,因此仍迫切需要安全有效的药物来治疗 SARS⁃CoV⁃2 染以控制新冠疫情在世界范围内的大流行。本文就已在临床投入使用的可用于治疗 COVID⁃19 的药物及 其有效性和安全性做一简要综述。

关键词:

新型冠状病毒肺炎, 药物, 治疗, 进展

Abstract:

From late December 2019,A form of COVID⁃19 caused by severe acute respiratory syndrome coronavirus 2(SARS⁃CoV⁃2)spread rapidly across the globe. Through active prevention,control and timely treat⁃ ment,the epidemic in China has been basically brought under control,with only local outbreaks and a few imported cases occurring in a few regions. However,the epidemic is still spreading in some countries and regions,and no specific drug is available for COVID⁃19 at present,so there is still an urgent need for effective and safe drugs to fight SARS⁃CoV⁃2 infection to control the pandemic of COVID⁃19 in the world. This article provides a brief review of the clinical use of drugs for the treatment of COVID⁃19 and their efficacy and safety.

Key words:

COVID?19, drugs, therapy, progress